Comparative Pharmacology
Head-to-head clinical analysis: DORIBAX versus INVANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIBAX versus INVANZ.
DORIBAX vs INVANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doripenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria.
Ertapenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1 g IV every 8 hours over 1 hour for complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital-acquired pneumonia (including ventilator-associated pneumonia).
1 g IV or IM once daily
None Documented
None Documented
Terminal elimination half-life approximately 1 hour in healthy adults; prolonged to ~4 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life approximately 4 hours; prolonged to approximately 8 hours in mild to moderate renal impairment (CrCl 30-59 mL/min) and to 14 hours in severe renal impairment (CrCl <30 mL/min); clinical context: requires dosage adjustment in renal impairment.
Renal: approximately 70-75% unchanged in urine; biliary/fecal: minimal (less than 20% total, primarily as metabolite).
Renal: ~80% unchanged in urine; biliary/fecal: ~10% as unchanged drug and the open-ring metabolite; minor hepatic metabolism.
Category C
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic